Krishna Chatterjee | |
---|---|
Born | [1] | 23 April 1958
Alma mater | Wolfson College, Oxford (BA, BMBCh) [1] |
Scientific career | |
Fields | |
Institutions | University of Cambridge |
Website | www |
Vengalil Krishna Kumar Chatterjee CBE FRS FRCP FMedSci [2] (born 23 April 1958) [1] is a British endocrinologist. He is a professor of endocrinology in the Department of Medicine at the University of Cambridge [3] and a fellow of Churchill College, Cambridge. [4] He is also the director of the Cambridge Clinical Research Centre, part of the National Institute for Health Research (NIHR). [5]
Chatterjee was born on 23 April 1958. He was educated at Wolfson College, Oxford, where he was awarded a Bachelor of Arts degree, and a Bachelor of Medicine, Bachelor of Surgery degree in 1982. [1] [6]
Chatterjee is distinguished for his discoveries of genetic disorders of thyroid gland formation, regulation of hormone synthesis and hormone action, which have advanced fundamental knowledge of the hypothalamic–pituitary–thyroid axis. [2] He has identified dominant negative inhibition by defective nuclear receptors as a common mechanism in thyroid hormone resistance and peroxisome proliferator-activated receptor gamma (PPARγ)-mediated insulin resistance. [2] [7] He has shown how deficiency of human selenocysteine-containing proteins causes a multisystem disease, including disordered thyroid hormone metabolism. He seeks to translate such understanding into better diagnosis and therapy of both rare and common thyroid conditions. [2]
Notable Cambridge scientists with whom Chatterjee has shared paper authorship include Sadaf Farooqi, Stephen O'Rahilly, Antonio Vidal-Puig, and Nick Wareham.
Chatterjee was appointed Commander of the Order of the British Empire (CBE) in the 2023 New Year Honours for services to people with endocrine disorders. [8]
In the field of molecular biology, the peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism, and tumorigenesis of higher organisms.
Thyroid hormone resistance (also resistance to thyroid hormone (RTH), and sometimes Refetoff syndrome) describes a rare syndrome in which the thyroid hormone levels are elevated but the thyroid stimulating hormone (TSH) level is not suppressed, or not completely suppressed as would be expected. The first report of the condition appeared in 1967. Essentially this is decreased end organ responsiveness to thyroid hormones. A new term "impaired sensitivity to thyroid hormone" has been suggested in March 2014 by Refetoff et al.
Sir Thomas Leon Blundell, is a British biochemist, structural biologist, and science administrator. He was a member of the team of Dorothy Hodgkin that solved in 1969 the first structure of a protein hormone, insulin. Blundell has made contributions to the structural biology of polypeptide hormones, growth factors, receptor activation, signal transduction, and DNA double-strand break repair, subjects important in cancer, tuberculosis, and familial diseases. He has developed software for protein modelling and understanding the effects of mutations on protein function, leading to new approaches to structure-guided and Fragment-based lead discovery. In 1999 he co-founded the oncology company Astex Therapeutics, which has moved ten drugs into clinical trials. Blundell has played central roles in restructuring British research councils and, as President of the UK Science Council, in developing professionalism in the practice of science.
Dame Kay Elizabeth Davies is a British geneticist. She is Dr Lee's Professor of Anatomy at the University of Oxford and a Fellow of Hertford College, Oxford. She is director of the Medical Research Council (MRC) functional genetics unit, a governor of the Wellcome Trust, a director of the Oxford Centre for Gene Function, and a patron and Senior Member of Oxford University Scientific Society. Her research group has an international reputation for work on Duchenne muscular dystrophy (DMD). In the 1980s, she developed a test which allowed for the screening of foetuses whose mothers have a high risk of carrying DMD.
James Julian Bennett Jack is a New Zealand physiologist.
Sir Stephen Patrick O'Rahilly is an Irish-British physician and scientist known for his research into the molecular pathogenesis of human obesity, insulin resistance and related metabolic and endocrine disorders.
Rajesh Vasantlal Thakker is May Professor of Medicine in the Nuffield Department of Clinical Medicine at the University of Oxford and a fellow of Somerville College, Oxford. Thakker is also a Consultant physician at the Churchill Hospital and the John Radcliffe Hospital, Principal investigator (PI) at the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) and was Chairman of the NIHR/MRC Efficacy and Mechanism Evaluation (EME) Board until Spring 2016.
Jane Clarke is an English biochemist and academic. Since October 2017, she has served as President of Wolfson College, Cambridge. She is also Professor of Molecular Biophysics, a Wellcome Trust Senior Research Fellow in the Department of Chemistry at the University of Cambridge. She was previously a Fellow of Trinity Hall, Cambridge. In 2023, she was elected to the National Academy of Sciences.
Annette Catherine Dolphin is a Professor of Pharmacology in the Department of Neuroscience, Physiology and Pharmacology at University College London (UCL).
Daniel Joshua Drucker is a Canadian endocrinologist. A Fellow of the Royal Society, he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes and other metabolic diseases.
Andrew Oliver Mungo Wilkie is a clinical geneticist who has been the Nuffield professor of Pathology at the University of Oxford since 2003.
David Alastair Standish Compston is a British neurologist. He is an emeritus professor of neurology in the Department of Clinical Neurosciences at the University of Cambridge and an emeritus fellow of Jesus College, Cambridge.
David Lodge is a research fellow in the Department of Physiology and Pharmacology at the University of Bristol.
Dimitri Michael Kullmann is a professor of neurology at the UCL Institute of Neurology, University College London (UCL), and leads the synaptopathies initiative funded by the Wellcome Trust. Kullmann is a member of the Queen Square Institute of Neurology Department of Clinical and Experimental Epilepsy and a consultant neurologist at the National Hospital for Neurology and Neurosurgery.
Ismaa Sadaf Farooqi is a Wellcome Trust Senior Research fellow in Clinical Science, professor of Metabolism and Medicine at the University of Cambridge and a consultant physician at Addenbrooke's Hospital in Cambridge, UK.
(Edith) Yvonne Jones is director of the Cancer Research UK Receptor Structure Research Group at the University of Oxford and a Fellow of Jesus College, Oxford. She is widely known for her research on the molecular biology of cell surface receptors and signalling complexes.
Anne Jacqueline Ridley is professor of Cell Biology and Head of School for Cellular and Molecular Medicine at the University of Bristol. She was previously a professor at King's College London.
Charles Nicholas "Nick" Hales (1935–2005) was an English physician, biochemist, diabetologist, pathologist, and professor of clinical biochemistry
Gurdyal Singh Besra is Bardrick Professor of Microbial Physiology & Chemistry at the University of Birmingham.
“All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” -- "Royal Society Terms, conditions and policies". Archived from the original on 2016-11-11. Retrieved 2016-03-09.{{cite web}}
: CS1 maint: bot: original URL status unknown (link)